Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today: https://g.foolcdn.com/editorial/images/764577/person-sitting-and-working-at-a-desk.jpg
If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today

It is customary to say that past success isn't a guarantee that a company will continue down that path -- a true statement. However, a corporation's track record provides vital information about its

If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today: https://g.foolcdn.com/editorial/images/764577/person-sitting-and-working-at-a-desk.jpg
If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today

It is customary to say that past success isn't a guarantee that a company will continue down that path -- a true statement. However, a corporation's track record provides vital information about its

These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy: https://g.foolcdn.com/editorial/images/764237/physician-talking-to-patient.jpg
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy

There are thousands of drugs on the market, and there are thousands more that are no longer in use. However, none has been more successful in terms of sales than AbbVie's (NYSE: ABBV) Humira. That's

2 Bargain Basement Stocks to Buy Now and Hold Forever: https://g.foolcdn.com/editorial/images/764141/getty-happy-couple-2.jpg
2 Bargain Basement Stocks to Buy Now and Hold Forever

Stocks across a range of sectors have been feeling the market volatility over the last few years. Even as stocks have rebounded considerably in recent months -- the S&P 500 is trading up by around

2 Bargain Basement Stocks to Buy Now and Hold Forever: https://g.foolcdn.com/editorial/images/764141/getty-happy-couple-2.jpg
2 Bargain Basement Stocks to Buy Now and Hold Forever

Stocks across a range of sectors have been feeling the market volatility over the last few years. Even as stocks have rebounded considerably in recent months -- the S&P 500 is trading up by around

1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?: https://g.foolcdn.com/editorial/images/764277/stock-market-chart-person-on-phone.jpg
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?

In biotech, it's often difficult to tell whether bad news for one company will also be bad news for a competitor, or vice versa. Between using different approaches to therapy development, working

Is Vertex Pharmaceuticals Stock a Buy Now?: https://g.foolcdn.com/editorial/images/764147/doctor-discussing-results-with-a-family.jpg
Is Vertex Pharmaceuticals Stock a Buy Now?

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been

Is Vertex Pharmaceuticals Stock a Buy Now?: https://g.foolcdn.com/editorial/images/764147/doctor-discussing-results-with-a-family.jpg
Is Vertex Pharmaceuticals Stock a Buy Now?

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been

Is Vertex Pharmaceuticals Stock a Buy Now?: https://g.foolcdn.com/editorial/images/764147/doctor-discussing-results-with-a-family.jpg
Is Vertex Pharmaceuticals Stock a Buy Now?

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been

2 Healthcare Stocks You Can Buy and Hold for the Next Decade: https://g.foolcdn.com/editorial/images/764139/getty-happy-person-sign-language-laptop.jpg
2 Healthcare Stocks You Can Buy and Hold for the Next Decade

Investing in healthcare stocks can be a fantastic way to diversify your portfolio with businesses that generate steady growth in a wide range of market environments. Not all healthcare stocks are

2 Healthcare Stocks You Can Buy and Hold for the Next Decade: https://g.foolcdn.com/editorial/images/764139/getty-happy-person-sign-language-laptop.jpg
2 Healthcare Stocks You Can Buy and Hold for the Next Decade

Investing in healthcare stocks can be a fantastic way to diversify your portfolio with businesses that generate steady growth in a wide range of market environments. Not all healthcare stocks are

2 Healthcare Stocks You Can Buy and Hold for the Next Decade: https://g.foolcdn.com/editorial/images/764139/getty-happy-person-sign-language-laptop.jpg
2 Healthcare Stocks You Can Buy and Hold for the Next Decade

Investing in healthcare stocks can be a fantastic way to diversify your portfolio with businesses that generate steady growth in a wide range of market environments. Not all healthcare stocks are

3 Stocks That Could Trounce the Market in 2024: https://g.foolcdn.com/editorial/images/764580/person-smiling-and-looking-at-laptop.jpg
3 Stocks That Could Trounce the Market in 2024

Arguably the most important quality for any stock is whether or not it beats the market. If it doesn't, you'd be better off putting your money in an index fund.

Three Motley Fool contributors think

3 Stocks That Could Trounce the Market in 2024: https://g.foolcdn.com/editorial/images/764580/person-smiling-and-looking-at-laptop.jpg
3 Stocks That Could Trounce the Market in 2024

Arguably the most important quality for any stock is whether or not it beats the market. If it doesn't, you'd be better off putting your money in an index fund.

Three Motley Fool contributors think

3 Stocks That Could Trounce the Market in 2024: https://g.foolcdn.com/editorial/images/764580/person-smiling-and-looking-at-laptop.jpg
3 Stocks That Could Trounce the Market in 2024

Arguably the most important quality for any stock is whether or not it beats the market. If it doesn't, you'd be better off putting your money in an index fund.

Three Motley Fool contributors think

Could Vertex Pharmaceuticals Reach $500 in 2024?: https://g.foolcdn.com/editorial/images/764714/gettyimages-906798262.jpg
Could Vertex Pharmaceuticals Reach $500 in 2024?

Vertex Pharmaceuticals (NASDAQ: VRTX) soared 85% over the past two years as it headed into a new era of growth. The company already has been a giant in the area of cystic fibrosis (CF) treatment for

Could Vertex Pharmaceuticals Reach $500 in 2024?: https://g.foolcdn.com/editorial/images/764714/gettyimages-906798262.jpg
Could Vertex Pharmaceuticals Reach $500 in 2024?

Vertex Pharmaceuticals (NASDAQ: VRTX) soared 85% over the past two years as it headed into a new era of growth. The company already has been a giant in the area of cystic fibrosis (CF) treatment for

Could Vertex Pharmaceuticals Reach $500 in 2024?: https://g.foolcdn.com/editorial/images/764714/gettyimages-906798262.jpg
Could Vertex Pharmaceuticals Reach $500 in 2024?

Vertex Pharmaceuticals (NASDAQ: VRTX) soared 85% over the past two years as it headed into a new era of growth. The company already has been a giant in the area of cystic fibrosis (CF) treatment for

These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?: https://g.foolcdn.com/editorial/images/764012/patient-talking-with-a-physician.jpg
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?

Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses

These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?: https://g.foolcdn.com/editorial/images/764012/patient-talking-with-a-physician.jpg
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?

Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses

These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?: https://g.foolcdn.com/editorial/images/764012/patient-talking-with-a-physician.jpg
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?

Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses

Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month: https://g.foolcdn.com/editorial/images/764656/gettyimages-663845678-600x400-bf06395.jpg
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month

January was a big month for pharmaceutical stocks, with Merck (NYSE: MRK), Eli Lilly (NYSE: LLY), and Novo Nordisk (NYSE: NVO) all climbing 11%, according to data provided by S&P Global Market

Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?: https://g.foolcdn.com/editorial/images/764024/vertex.png
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?

Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders know just how good it can be to ride a biopharma stock upward as it notches positive milestones year after year. With its shares up by 99% in the

Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?: https://g.foolcdn.com/editorial/images/764024/vertex.png
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?

Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders know just how good it can be to ride a biopharma stock upward as it notches positive milestones year after year. With its shares up by 99% in the

Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?: https://g.foolcdn.com/editorial/images/764024/vertex.png
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?

Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders know just how good it can be to ride a biopharma stock upward as it notches positive milestones year after year. With its shares up by 99% in the